The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II trial of upfront docetaxel and vinorelbine followed by either maintenance oral vinorelbine or observation in patients with HER2-negative locally advanced (LA) or metastatic (M) breast cancer (BC).
Fadi Sami Farhat
No relevant relationships to disclose
Marwan Ghosn
No relevant relationships to disclose
Nizar Bitar
No relevant relationships to disclose
Moussa Dehaini
No relevant relationships to disclose
Georges Y. Chahine
No relevant relationships to disclose
Cynthia Mourad
Employment or Leadership Position - Pierre Fabre Medicament
Ahmed Othman
No relevant relationships to disclose
Mayssam El-Mouhebb
No relevant relationships to disclose
Joseph Gergi Kattan
No relevant relationships to disclose